Trimel Pharmaceuticals Corporation
TSX : TRL

Trimel Pharmaceuticals Corporation

October 29, 2013 16:48 ET

Trimel to Report Third Quarter 2013 Results and Host Investor Call

TORONTO, ONTARIO--(Marketwired - Oct. 29, 2013) - Trimel Pharmaceuticals Corporation (TSX:TRL) will report its third quarter financial results for the period ended September 30, 2013 on Sunday, November 3, 2013.

Management of the Company will host a conference call to discuss these results and update investors on the status of its business on Monday, November 4, 2013, at 8:30 a.m. Eastern Standard Time. Following the discussion, Trimel executives will address inquiries from investment analysts.

To access the call live, please dial 416-340-2216 (Toronto), 1-866-223-7781 (Canada and U.S.) or 00-800-6578-9898 (International). Listeners are encouraged to dial in 10 minutes before the call begins to avoid delays.

A replay of the conference call will be available until 7:00 p.m. Eastern Standard Time on Monday, November 11, 2013 by dialing 905-694-9451 (Toronto), 1-800-408-3053 (Canada and U.S.) or 00-800-3366-3052 (International), using access code: 5944011#.

For further information regarding Trimel Pharmaceuticals Corporation, please contact Kenneth Howling, Chief Financial Officer at (416) 679-0536 or via email at ir@trimelpharmaceuticals.com.

About Trimel

Trimel is a specialty pharmaceutical company actively developing medications for male hypogonadism, female sexual dysfunction and various respiratory disorders. A New Drug Application for CompleoTRT, a product using Trimel's licensed bioadhesive intranasal technology, has been accepted for review by the FDA for regulatory approval in the United States. For more information, please visit www.trimelpharmaceuticals.com.

Contact Information